Overview Dividends

(PEN) Penumbra - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US70975L1070

Thrombectomy, Embolization, Access, Neurosurgical, Coils

Health Care Equipment
Market Cap in USD: 12,118m

IPO / Inception: 2015-09-18
Return 12m vs S&P 500: 13.6%

EPS (Earnings per Share)

EPS CAGR: 4.68%
EPS Trend: 64.2%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 15.89%
Rev. Trend: 98.7%

Last SUE: 2.97
Qual. Beats: 4

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	41.4%
Value at Risk 5%th	57.8%
Relative Tail Risk	-15.20%

Reward TTM
Sharpe Ratio	0.77
Alpha	17.33
CAGR/Max DD	0.23

Character TTM
Hurst Exponent	0.505
Beta	0.680
Beta Downside	0.634

Drawdowns 3y
Max DD	52.44%
Mean DD	24.87%
Median DD	26.29%

Description: PEN Penumbra January 06, 2026

Penumbra, Inc. (NYSE:PEN) designs, develops, manufactures, and markets a broad suite of minimally invasive medical devices for neurovascular and peripheral interventions, selling primarily through a direct sales force and a network of distributors.

Its product lineup includes the Indigo aspiration system, Lightning Flash and Lightning Bolt mechanical thrombectomy devices, a range of guide and delivery catheters (Neuron, BMX, MIDWAY, etc.), the Penumbra Engine integrated thrombectomy platform, and neuro-embolization coils (Coil 400, SMART COIL, SwiftPAC). Peripheral embolization tools such as the Ruby Coil System and the POD occlusion device round out the portfolio, complemented by neurosurgical tools like the Artemis Neuro Evacuation Device.

Recent financial data show FY 2023 revenue of approximately $1.22 billion, up 12 % year-over-year, with an operating margin of 15 % and free cash flow generation of $180 million, reflecting strong demand for its high-margin consumables. The company secured FDA clearance for an upgraded Indigo System in Q1 2024 and announced a strategic partnership to expand distribution in China, a market projected to grow 8 % annually for neuro-interventional devices.

Key sector drivers include an aging U.S. population, rising incidence of ischemic stroke and peripheral artery disease, and a broader shift toward cost-effective, catheter-based therapies that reduce hospital stays-trends that historically boost demand for Penumbra’s product categories.

For a deeper quantitative view, consult ValueRay’s detailed valuation model to assess PEN’s upside potential.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (164.0m TTM) > 0 and > 6% of Revenue (6% = 80.0m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA -0.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 72.87% (prev 63.46%; Δ 9.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 203.3m > Net Income 164.0m (YES >=105%, WARN >=100%)

Net Debt (-104.0m) to EBITDA (204.5m) ratio: -0.51 <= 3.0 (WARN <= 3.5)

Current Ratio 6.73 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (39.3m) change vs 12m ago 0.32% (target <= -2.0% for YES)

Gross Margin 66.80% (prev 62.84%; Δ 3.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 82.75% (prev 78.68%; Δ 4.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 142.2 (EBITDA TTM 204.5m / Interest Expense TTM 1.32m) >= 6 (WARN >= 3)

Altman Z'' 5.32

(A) 0.56 = (Total Current Assets 1.14b - Total Current Liabilities 169.6m) / Total Assets 1.74b

(B) 0.11 = Retained Earnings (Balance) 190.3m / Total Assets 1.74b

(D) 0.50 = Book Value of Equity 193.5m / Total Liabilities 385.7m

Total Rating: 5.32 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 77.07

1. Piotroski 6.0pt

2. FCF Yield 1.27%

3. FCF Margin 11.44%

4. Debt/Equity 0.16

5. Debt/Ebitda -0.51

6. ROIC - WACC (= 4.70)%

7. RoE 13.08%

8. Rev. Trend 98.74%

9. EPS Trend 64.18%

What is the price of PEN shares?

As of January 07, 2026, the stock is trading at USD 316.97 with a total of 623,275 shares traded.
Over the past week, the price has changed by +0.86%, over one month by +7.51%, over three months by +24.01% and over the past year by +33.58%.

Is PEN a buy, sell or hold?

Penumbra has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy PEN.

Strong Buy: 12
Buy: 2
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the PEN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	327.9	3.5%
Analysts Target Price	327.9	3.5%
ValueRay Target Price	318.6	0.5%

PEN Fundamental Data Overview January 04, 2026

Market Cap USD = 12.12b (12.12b USD * 1.0 USD.USD)
P/E Trailing = 74.0239
P/E Forward = 60.9756
P/S = 9.085
P/B = 8.9615
P/EG = 0.7184
Beta = 0.662
Revenue TTM = 1.33b USD
EBIT TTM = 187.1m USD
EBITDA TTM = 204.5m USD
Long Term Debt = 21.2m USD (from longTermDebtTotal, last quarter)
Short Term Debt = 15.5m USD (from shortTermDebt, last quarter)
Debt = 217.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -104.0m USD (from netDebt column, last quarter)
Enterprise Value = 12.01b USD (12.12b + Debt 217.0m - CCE 321.0m)
Interest Coverage Ratio = 142.2 (Ebit TTM 187.1m / Interest Expense TTM 1.32m)
FCF Yield = 1.27% (FCF TTM 152.6m / Enterprise Value 12.01b)
FCF Margin = 11.44% (FCF TTM 152.6m / Revenue TTM 1.33b)
Net Margin = 12.30% (Net Income TTM 164.0m / Revenue TTM 1.33b)
Gross Margin = 66.80% ((Revenue TTM 1.33b - Cost of Revenue TTM 442.8m) / Revenue TTM)
Gross Margin QoQ = 67.78% (prev 65.99%)
Tobins Q-Ratio = 6.89 (Enterprise Value 12.01b / Total Assets 1.74b)
Interest Expense / Debt = 0.16% (Interest Expense 338.0k / Debt 217.0m)
Taxrate = 12.37% (6.47m / 52.3m)
NOPAT = 164.0m (EBIT 187.1m * (1 - 12.37%))
Current Ratio = 6.73 (Total Current Assets 1.14b / Total Current Liabilities 169.6m)
Debt / Equity = 0.16 (Debt 217.0m / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = -0.51 (Net Debt -104.0m / EBITDA 204.5m)
Debt / FCF = -0.68 (Net Debt -104.0m / FCF TTM 152.6m)
Total Stockholder Equity = 1.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.40% (Net Income 164.0m / Total Assets 1.74b)
RoE = 13.08% (Net Income TTM 164.0m / Total Stockholder Equity 1.25b)
RoCE = 14.67% (EBIT 187.1m / Capital Employed (Equity 1.25b + L.T.Debt 21.2m))
RoIC = 13.08% (NOPAT 164.0m / Invested Capital 1.25b)
WACC = 8.37% (E(12.12b)/V(12.33b) * Re(8.52%) + D(217.0m)/V(12.33b) * Rd(0.16%) * (1-Tc(0.12)))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 1.31%
[DCF Debug] Terminal Value 79.91% ; FCFE base≈145.2m ; Y1≈179.2m ; Y5≈305.7m
Fair Price DCF = 121.1 (DCF Value 4.74b / Shares Outstanding 39.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 64.18 | EPS CAGR: 4.68% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.74 | Revenue CAGR: 15.89% | SUE: 2.97 | # QB: 4
EPS next Quarter (2026-03-31): EPS=1.09 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=14
EPS next Year (2026-12-31): EPS=5.02 | Chg30d=+0.004 | Revisions Net=+0 | Growth EPS=+33.2% | Growth Revenue=+14.2%

Additional Sources for PEN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle